---
schema_version: "secwatch.filing_event.v1"
accession: "0001376339-25-000104"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:36:41.226569+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q3 record revenue $114M (+35% YoY); raises FY2025 guidance

## Summary
- Q3 net sales $114M, up 35% YoY; GAAP net income $17M, diluted EPS $0.11.
- Adjusted EBITDA $35M, 31% of net sales; Wound product sales grew 40%, Surgical 26%.
- Cash and equivalents $142M at Sept 30, up from $104M at Dec 31, 2024.
- 2025 outlook raised: net sales growth mid-to-high teens, adjusted EBITDA margin at least mid-20%.
- CEO cites record revenue, cash flow; awaiting final 2026 CMS reimbursement rules.

## SEC filing metadata
- accession: 0001376339-25-000104
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000137633925000104/0001376339-25-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000137633925000104/mdxg-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001376339-25-000104
- JSON: https://secwatch.observer/filing/0001376339-25-000104.json
- Plain text: https://secwatch.observer/filing/0001376339-25-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.